| Literature DB >> 25939380 |
Ascanio Tridente1,2, Geraldine M Clarke3, Andrew Walden4, Anthony C Gordon5, Paula Hutton6, Jean-Daniel Chiche7, Paul A H Holloway8, Gary H Mills9,10, Julian Bion11, Frank Stüber12, Christopher Garrard13, Charles Hinds14.
Abstract
INTRODUCTION: Patients admitted to intensive care following surgery for faecal peritonitis present particular challenges in terms of clinical management and risk assessment. Collaborating surgical and intensive care teams need shared perspectives on prognosis. We aimed to determine the relationship between dynamic assessment of trends in selected variables and outcomes.Entities:
Mesh:
Year: 2015 PMID: 25939380 PMCID: PMC4432819 DOI: 10.1186/s13054-015-0931-8
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Trends in variables during first 7 days of intensive care unit stay
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||
| Organ failure and support | ||||||||
| ARF | 974 | 283 | 29.1% | 659 | 159 | 24.1% | ||
| RRT | 974 | 115 | 11.8% | 659 | 104 | 15.8% | ||
| Ventilatory support | 974 | 743 | 76.3% | 657 | 413 | 62.9% | ||
| Inotrope/vasopressor useb | 974 | 660 | ||||||
| None | 267 | 27.4% | 434 | 65.8% | ||||
| A | 33 | 3.4% | 36 | 5.5% | ||||
| B | 169 | 17.4% | 105 | 15.9% | ||||
| C | 505 | 51.9% | 85 | 12.9% | ||||
| SOFA | 974 | 7 | 5 to 10 | 659 | 5 | 2 to 8 | ||
| GCS SOFA | 974 | 0 | 0 to 1 | 674 | 0 | 0 to 1 | ||
| CVS SOFA | 974 | 4 | 1 to 4 | 671 | 1 | 0 to 3 | ||
| Coagulation SOFA | 974 | 0 | 0 to 1 | 674 | 0 | 0 to 1 | ||
| Respiratory SOFA | 974 | 2 | 2 to 3 | 659 | 2 | 1 to 3 | ||
| Renal SOFA | 974 | 1 | 0 to 2 | 674 | 0 | 0 to 1 | ||
| Bilirubin SOFA | 974 | 0 | 0 to 1 | 674 | 0 | 0 to 0 | ||
| Laboratory variables | ||||||||
| Serum bicarbonate | 893 | 21 | 18 to 24 | 580 | 26 | 23 to 29.1 | ||
| paO2 (kPa) | 945 | 11.3 | 9.6 to 13.9 | 590 | 10.8 | 9.2 to 13.6 | ||
| paCO2 (kPa) | 938 | 5.2 | 4.6 to 6 | 535 | 5.2 | 4.7 to 6 | ||
| Highest creatinine (μmol/L) | 974 | 106.6 | 76 to 160 | 654 | 81.5 | 53.9 to 132 | ||
| Lowest creatinine (μmol/L) | 974 | 100 | 70 to 144 | 642 | 81.5 | 54 to 130 | ||
| Highest WCC (10−9/L) | 974 | 12 | 7.1 to 18 | 643 | 15.3 | 11 to 20.4 | ||
| Lowest WCC (10−9/L) | 974 | 9.4 | 4.6 to 15 | 643 | 15 | 10.5 to 20 | ||
| Lowest platelets (10−9/L) | 974 | 212.5 | 145 to 300 | 640 | 234.5 | 132 to 352.5 | ||
| Highest bilirubin (mmol/L) | 974 | 13 | 8 to 22 | 650 | 10 | 5 to 19 | ||
| Highest urea (mmol/L) | 908 | 11 | 6.4 to 17.1 | 607 | 11.6 | 7.2 to 20.8 | ||
| Chest radiography findings | ||||||||
| Localised infiltrates | 973 | 115 | 11.8% | 672 | 68 | 10.1% | ||
| Lobar infiltrates | 973 | 61 | 6.3% | 672 | 32 | 4.8% | ||
| Diffuse bilateral infiltrates | 973 | 148 | 15.2% | 672 | 109 | 16.2% | ||
| Physiological parameters | ||||||||
| Highest temperature (°C) | 974 | 37.7 | 37 to 38.3 | 656 | 37.4 | 37 to 38 | ||
| Lowest temperature (°C) | 974 | 36.2 | 35.7 to 36.9 | 656 | 36.5 | 36 to 37 | ||
| Highest SBP (mmHg) | 974 | 140 | 125 to 155 | 655 | 150 | 135 to 170 | ||
| Lowest SBP (mmHg) | 972 | 90 | 80 to 100 | 655 | 108 | 95 to 120 | ||
| Highest MAP (mmHg) | 972 | 91 | 82 to 103 | 649 | 98 | 89 to 110 | ||
| Lowest MAP (mmHg) | 970 | 62 | 56 to 70 | 649 | 71 | 63 to 80 | ||
| Highest heart rate (bpm) | 974 | 117 | 103 to 130 | 655 | 104 | 90 to 118 | ||
| Lowest heart rate (bpm) | 971 | 85 | 73 to 99 | 655 | 80 | 70 to 90 | ||
| Respiratory rate (breaths/min) | 966 | 18 | 14 to 24 | 638 | 20 | 16 to 27 | ||
| Urinary volume (ml/24 hr) | 973 | 1,375 | 790 to 2,100 | 644 | 2,276.5 | 1,333.5 to 3,411.5 | ||
| paO2/FiO2 ratio (kPa) | 942 | 27.8 | 19.6 to 37.7 | 573 | 30.7 | 23.1 to 39.2 | ||
aARF, Acute renal failure; bpm, Beats per minute; CVS, Cardiovascular; GCS, Glasgow Coma Scale; IQR, Interquartile range; MAP, Mean arterial pressure; n, Absolute count; N, Number of non-missing observations; paCO2, Arterial partial pressure of carbon dioxide; paO2, Arterial partial pressure of oxygen; paO2/FiO2, Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; RRT, Renal replacement therapy; SBP, Systolic blood pressure; SOFA, Sequential Organ Failure Assessment; WCC, White cell count. bInotropic and vasopressor use is coded as follows: A = dopamine ≤5 μg/kg/min or dobutamine; B = dopamine >5 μg/kg/min or adrenaline/noradrenaline ≤0.1 μg/kg/min; C = dopamine >15 μg/kg/min or adrenaline/noradrenaline >0.1 μg/kg/min.
Factors independently associated with 6-month, intensive care unit, hospital and 28-day mortality, after adjustment for age and sex
|
|
|
|
| |
|---|---|---|---|---|
| 6-month mortality | ||||
| Deterioration of thrombocytopaenia (10 × 10−9/L platelets) | 1.02 | 1.01 to 1.03 | <0.001 | |
| Decrease in daily urinary volume (100 ml) | 1.02 | 1.01 to 1.03 | <0.001 | |
| Decrease in highest recorded bilirubin (mmol/L) | 0.99 | 0.99 to 0.99 | 0.020 | |
| Improvement in GCS SOFA score (1 point) | 0.81 | 0.68 to 0.98 | 0.028 | |
| Improvement in renal SOFA score (1 point) | 0.87 | 0.75 to 0.99 | 0.047 | |
| ICU mortality | ||||
| Decrease in daily urinary volume (100 ml) | 1.02 | 1.01 to 1.03 | 0.005 | |
| Improvement in total SOFA score (1 point) | 0.91 | 0.85 to 0.98 | 0.009 | |
| Hospital mortality | ||||
| Deterioration of thrombocytopaenia (10 × 10−9/L platelets) | 1.02 | 1.01 to 1.03 | 0.001 | |
| Decrease in daily urinary volume (100 ml) | 1.02 | 1.01 to 1.03 | <0.001 | |
| Improvement in GCS SOFA score (1 point) | 0.8 | 0.68 to 0.95 | 0.011 | |
| Improvement in renal SOFA score (1 point) | 0.87 | 0.77 to 0.99 | 0.043 | |
| 28-day mortality | ||||
| Decrease in daily urinary volume (100 ml) | 1.02 | 1.01 to 1.03 | 0.001 | |
| Improvement in GCS SOFA score (1 point) | 0.75 | 0.61 to 0.93 | 0.010 | |
| Improvement in renal SOFA score (1 point) | 0.79 | 0.66 to 0.95 | 0.013 | |
aCI, Confidence interval; GCS, Glasgow Coma Scale; HR, Hazard ratio; ICU, Intensive care unit; SOFA, Sequential Organ Failure Assessment.
Figure 1Trends in variables independently associated with 6-month survival (primary outcome). (A1) to (A3) Daily lowest platelet count, 24-hour urinary volume and highest recorded bilirubin concentration. The boxes indicate median and interquartile range (IQR), the whiskers extend to include 1.5× IQR and the dots include outliers outside this range. (B1) and (B2) Daily Glasgow Coma Scale (GCS) score and renal components of the Sequential Organ Failure Assessment (SOFA) score. Proportions of different values of the renal and GCS components of the SOFA are indicated for survivors and non-survivors.
Trends during first 7 days of the intensive care unit stay (in survivors and non-survivors at 6 months) for variables independently associated with outcomes in multivariate analyses
|
|
| ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| Lowest platelets (*109/L) | |||||||
| Survivors | 667 | 226 | 159 to 316 | 426 | 267 | 164 to 388 | |
| Non-survivors | 307 | 185 | 113 to 280 | 214 | 146 | 78 to 274 | |
| Urinary volume (ml/24 hours) | |||||||
| Survivors | 666 | 1,499 | 916 to 2,170 | 429 | 2460 | 1,680 to 3,633 | |
| Non-survivors | 307 | 1,080 | 475 to 1,915 | 215 | 1750 | 471 to 2,774 | |
| Highest bilirubin (mmol/L) | |||||||
| Survivors | 667 | 13 | 8 to 21 | 433 | 9 | 5 to 17 | |
| Non-survivors | 307 | 14 | 8 to 25 | 217 | 14 | 6 to 25 | |
| GCS SOFA score | |||||||
| Survivors | 667 | 0 | 0 to 0 | 453 | 0 | 0 to 0 | |
| Non-survivors | 307 | 0 | 0 to 2 | 221 | 1 | 0 to 2 | |
| Renal SOFA score | |||||||
| Survivors | 667 | 0 | 0 to 1 | 453 | 0 | 0 to 1 | |
| Non-survivors | 307 | 1 | 0 to 3 | 221 | 1 | 0 to 3 | |
aGCS, Glasgow Coma Scale; IQR, Interquartile range; n, Absolute count; N, Number of non-missing observations; SOFA, Sequential Organ Failure Assessment.